Non-aneurysmal subarachnoid haemorrhage in COVID-19

Suzanne Harrogate1 · Alex Mortimer1 · Lorna Burrows1 · Barnaby Fiddes1 · Ian Thomas1 · Claire M Rice1,2*

Received: 25 July 2020 / Accepted: 20 August 2020
© The Author(s) 2020

Abstract
Coronavirus disease of 2019 (COVID-19) is associated with hypercoagulopathy, but haemorrhage, including spontaneous intracerebral parenchymal haemorrhage and diffuse petechial cerebral haemorrhage, has also been reported. We present two cases of nonaneurysmal subarachnoid haemorrhage (SAH) in patients with severe COVID-19. Careful review of neuroimaging for haemorrhagic complications of COVID-19 should be undertaken, particularly for those patients receiving enhanced prophylaxis for venous thromboembolism. Although likely to be a marker of severe disease, non-aneurysmal SAH can be associated with favourable outcome.

Keywords Subarachnoid haemorrhage · COVID-19 · Clinical neurology · Neuroradiology

Introduction
Although a predisposition to thrombosis in COVID-19 is well-recognised [1, 2], reports of haemorrhage affecting multiple organ systems, including the CNS are emerging [3, 4]. The pathophysiology is not yet fully understood and may be multifactorial including microthrombosis with secondary haemorrhage, dysregulated coagulation, e.g. disseminated intravascular coagulation and immune thrombocytopenic purpura [5], and vascular hyperpermeability in the context of COVID-19 cytokine storm [1], endotheliitis [6] and vasculitis [7].

We report 2 cases of non-aneurysmal SAH in severe COVID-19 and hypothesise that this occurred as a complication of thromboembolic disease in the context of enhanced prophylaxis for thromboembolic disease. These cases add to the clinical spectrum of neurological complications associated with COVID-19 and highlight the importance of careful review of neuroimaging in patients with severe COVID-19.

Patient A
A 74-year-old gentleman with confirmed COVID-19 and type 1 respiratory failure was admitted to the intensive care unit for mechanical ventilatory support. Maximum blood pressure was 130/55 mmHg. He received enoxaparin 40 mg bd subcutaneously as enhanced prophylaxis for venous thromboembolism [8]. Markers of disease severity included fibrinogen > 6 g/L, D-dimer assay value 55 μg/ml, ferritin 1808 μg/L and neutrophil:lymphocyte ratio 13. [9] At day 11, a CT head scan performed for reduced conscious level following sedation hold demonstrated multifocal, small volume, convexity SAH (Figs. 1 and 2). CSF analysis confirmed SAH (red blood cells 7614/mm³, white blood cells <5/mm³, protein 1.1 g/L, negative for viral studies including SAR-CoV-2). The platelet count transiently fell 3 days prior to CT head scan (36 × 10⁹/L), but clotting studies were otherwise normal. A weakly positive lupus anticoagulant was detected together with anti-cardiolipin IgG antibodies (55 GPLU). Beta-2-glycoprotein 1 IgG and IgM were normal (<10 U/ml). Paroxysmal atrial fibrillation was noted. Electroencephalogram was consistent...
with encephalopathy. An MRI brain scan demonstrated SAH with small multifocal infarcts and normal magnetic resonance angiography appearances (Fig. 1); SAH colocalised with areas of infarction but was also more widely distributed. On transthoracic echocardiography, a pedunculated mobile mass consistent with thrombus was seen within the left atrium attached to the inferior limbic band region. Blood cultures were sterile. Anticoagulation was held for 2 weeks, and interval neuroimaging excluded additional intracranial haemorrhage or new infarction following which he was fully anticoagulated. The mobile structure within the left atrium was reduced in size on follow-up transthoracic echocardiography. With continued supportive therapies, his level of consciousness improved, and he has been discharged for ongoing rehabilitation.

**Patient B**

A 53-year-old gentleman with confirmed COVID-19 and type 1 respiratory failure required mechanical ventilatory support. Markers of disease severity included ferritin 2107 μg/L, fibrinogen > 6 g/L, d-dimer assay value 18.5 μg/ml and neutrophil:lymphocyte ratio 32. Maximum blood pressure was 152/60 mmHg. Enoxaparin was given 40 mg bd subcutaneously [8]. Raised clozapine level (4.6 mg/L, normal range 0.35–0.6 mg/L) was noted. CT head scan following seizure activity on sedation withdrawal demonstrated multifocal, curvilinear foci of sulcal high density consistent with SAH which was not present on historical imaging (Fig. 1). Coagulation studies were normal throughout. Electroencephalogram was consistent with encephalopathy. CSF analysis and MRI brain scan (complicated by motion artefact), performed > 7 days later, were normal. Blood tests were satisfactory with the exception of oligoclonal pattern on serum immunofixation. With continued supportive therapies, his level of consciousness improved. He has subsequently been discharged from the intensive care unit for continued rehabilitation.

**Discussion**

We report 2 cases of nonaneurysmal SAH which have occurred in patients with severe COVID-19. We have attributed this to thromboembolism in the context of enhanced venous thromboembolism prophylaxis; alternative causes for nonaneurysmal SAH including reversible cerebral vasoconstriction syndrome, posterior reversible encephalopathy syndrome or cerebral amyloid angiopathy were considered unlikely based on the investigation results.

These cases highlight that, although prophylaxis and treatment of thrombosis associated with COVID-19 are undoubtedly important, clinicians should be alert to the possibility of haemorrhagic complications, particularly those associated with thromboembolic disease. Careful review of neuroimaging for subtle changes consistent with nonaneurysmal subarachnoid haemorrhage is required. Although likely to be a marker of severe disease due to COVID-19, SAH can be associated with a favourable outcome.
Authors’ contributions All authors contributed to the conception of the work, data acquisition and interpretation, manuscript drafting, critically revising the manuscript for important intellectual content and approved the final version.

Funding information No specific funding for the study.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethics approval N/A—retrospective case series and not an intervention- al research study so research ethics committee approval is not required.

Consent to participation N/A—retrospective case reports but see consent for publication.

Consent for publication Written informed consent for publication has been given by patient A and from patient B’s next of kin.

Code availability N/A.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Jose RJ, Manuel A (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 8:e46–e47. https://doi.org/10.1016/S2213-2600(20)30216-2

2. Bikdeli B, Madhavan MV, Jimenez D, Chuih T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Querei D, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Constantinides SV, Weitz JI, Lip GYH (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 75:2950–2973. https://doi.org/10.1016/j.jacc.2020.04.031

3. Benger M, Williams O, Siddiqui J, Sztria L (2020) Intracerebral haemorrhage and COVID-19: clinical characteristics from a case series. Brain Behav Immun 88:940–944. https://doi.org/10.1016/j.bbi.2020.06.005
4. von Weyhern CH, Kaufmann I, Neff F, Kremer M (2020) Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 395:e109. https://doi.org/10.1016/S0140-6736(20)31282-4
5. Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andres E (2020) Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med 382(18):e43. https://doi.org/10.1056/NEJMc201047
6. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418. https://doi.org/10.1016/S0140-6736(20)30937-5
7. Hanafi R, Roger PA, Perin B, Kuchcinski G, Deleval N, Dallery F, Michel D, Hacein-Bey L, Pruvo JP, Outteryck O, Constans JM (2020) COVID-19 neurologic complication with CNS vasculitis-like pattern. AJNR Am J Neuroradiol 41:1384–1387. https://doi.org/10.3174/ajnr.A6651
8. British Thoracic Society Guidance on Venous Thromboembolic Disease in Patients with COVID-19 (2020) https://www.univadis.co.uk/viewarticle/british-thoracic-society-issues-guidance-on-vte-in-patients-with-covid-19-718833. Accessed 2020/05/19
9. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang Y, Tang L, Deng J, Mei H, Hu Y (2020) Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. https://doi.org/10.1016/S2352-3026(20)30217-9

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.